Unichem Labs gets USFDA approval for treatment of hypertension

Pharma major, Unichem Laboratories has received ANDA approval from the USFDA for Losartan Potassium and Hydrochlorothiazide tablets USP.

Jul 25, 2017 06:07 IST India Infoline News Service

Pharma major, Unichem Laboratories has received ANDA approval from the USFDA for Losartan Potassium and Hydrochlorothiazide tablets USP.
 
Losartan Potassium and Hydrochlorothiazide is a combination of Losartan Potassium, an angiotensin II receptor blocker (ARB) and Hydrochlorothiazide. The company's newly approved tablet is indicated for the treatment of hypertension and for reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
 
It also said that the product will be commercialised from its Ghaziabad plant.
 
Unichem Laboratories was trading at Rs 277, up by Rs 5.30 or 1.95% as at 1123 hours on Tuesday, on the BSE. The stock has attracted traded volume of 1,65,031 shares and traded value of Rs 459.43 lakh on the NSE.
 
Stock view:
 
Unichem Laboratories Ltd is currently trading at Rs 277.1, up by Rs 5.4 or 1.99% from its previous closing of Rs 271.7 on the BSE.
 
The scrip opened at Rs 273.55 and has touched a high and low of Rs 282 and Rs 273.25 respectively. So far 200411(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 2470.27 crore.
 
The BSE group 'B' stock of face value Rs 2 has touched a 52 week high of Rs 319.9 on 20-Oct-2016 and a 52 week low of Rs 239.05 on 30-May-2017. Last one week high and low of the scrip stood at Rs 275 and Rs 269.05 respectively.
 
The promoters holding in the company stood at 50.06 % while Institutions and Non-Institutions held 17.33 % and 32.62 % respectively.
 
The stock is currently trading above its 200 DMA.

Related Story